Safety and Effectiveness of Cyberknife-Based Stereotactic Body Radiotherapy in Older Patients with Biopsy Proven Early Stage Non-Small Cell Lung Cancer: A Community Cancer Center Experience from the International Geriatric Radiotherapy Group

Juan Godinez1 , Paul Vos2 , Vincent Vinh-Hung3 , Ulf Karlsson4 , Julio Alvarenga5 , Wei Shen6 , Alexander Chi7 , Satya Bose8 , Thandeka Mazibuko4 , Gokoulakrichenane Loganadane9 , Alejandro Chagoya Gonzalez10, Anabella Villoria11, Nam P Nguyen8*, Meritxell Arenas12

1Cancer Center at Wise Health System, Decatur, TX, USA 2 Department of Biostatistics, East Carolina University, Greenville, NC, USA 3 Department of Radiation Oncology, University of Martinique, Martinique, France 4 Department of Radiation Oncology, International Geriatric Radiotherapy Group, Washington, DC, USA 5Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, CA, USA 6Department of Pulmonary and Critical Care, Loma Linda University, CA, USA 7 Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, China 8 Department of Radiation Oncology, Howard University, Washington, DC, USA 9 Department of Radiation Oncology, CHU Mondor, University Paris Est, Creteil, Creteil, France 10Department of Radiation Oncology, Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, Mexico 11Department of Radiation Oncology, Clinica El Avila, Caracas, Venezuela 12Department of Radiation Oncology, Sant Joan de Reus University, Tarragona, Spain

^*Correspondance to: Nam P Nguyen 

 PDF  Full Text DOI: 10.25107/2474-1647.3090

Abstract

The aim of this article is to assess the safety and efficacy of cyberknife-based Stereotactic Body Radiotherapy (SBRT) among older patients (at least 70 years-old) whose medical conditions preclude surgery for their early stage Non-Small Cell Lung Cancer (NSCLC). A retrospective review of older patients with a median age of 82 (range: 70 to 88 year-old) who had cyberknife-based SBRT for early stage biopsy proven NSCLC in a community hospital was performed. Morbidity, complications, and local control were assessed. Among 33 older patients who had SBRT for early stage NSCLC, no patient developed grade 3 to 4 complications at a median follow-up of 19 months (range: 5 to 32 months). Only two patients (6%) developed local recurrences. Cyberknife-based SBRT is safe and effective for local control in older patients with early stage biopsy proven NSCLC whose medical conditions preclude surgery

Keywords

Older; Lung cancer; Early stage; Co-morbidity; SBRT

Cite the article

Godinez J, Vos P, Vinh-Hung V, Karlsson U, Alvarenga J, Shen W, et al. Safety and Effectiveness of CyberknifeBased Stereotactic Body Radiotherapy in Older Patients with Biopsy Proven Early Stage Non-Small Cell Lung Cancer: A Community Cancer Center Experience from the International Geriatric Radiotherapy Group. Clin Surg. 2021; 6: 3090..